(Q39496607)

12 September 2017

Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion (English)

1 reference

12 September 2017

0 references

1 reference

Mitsushige Sugimoto

1

1 reference

12 September 2017

Takahiro Uotani

2

1 reference

12 September 2017

Shu Sahara

3

1 reference

12 September 2017

Hitomi Ichikawa

4

1 reference

12 September 2017

Mihoko Yamade

5

1 reference

12 September 2017

Ken Sugimoto

6

1 reference

12 September 2017

Takahisa Furuta

7

1 reference

12 September 2017

1 April 2014

1 reference

12 September 2017

1 reference

12 September 2017

19

1 reference

12 September 2017

4

1 reference

12 September 2017

312-318

1 reference

Helicobacter pylori infection and the development of gastric cancer

12 September 2017

1 reference

Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial

21 January 2018

1 reference

Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review

21 January 2018

1 reference

A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients

21 January 2018

1 reference

Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin

21 January 2018

1 reference

Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance

21 January 2018

1 reference

Furazolidone-based triple therapy for H pylori gastritis in children

21 January 2018

1 reference

Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities

21 January 2018

1 reference

Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance

21 January 2018

1 reference

New concepts of resistance in the treatment of Helicobacter pylori infections

21 January 2018

1 reference

Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin

21 January 2018

1 reference

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

21 January 2018

1 reference

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

21 January 2018

1 reference

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole

21 January 2018

1 reference

Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype

21 January 2018

1 reference

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

21 January 2018

1 reference

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

21 January 2018

1 reference

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

21 January 2018

1 reference

Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups

21 January 2018

1 reference

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

21 January 2018

1 reference

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

The life and death of Helicobacter pylori

21 January 2018

1 reference

The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin

21 January 2018

1 reference

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

21 January 2018

1 reference

In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis

21 January 2018

1 reference

Pharmacogenomics of proton pump inhibitors

21 January 2018

1 reference

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/HEL.12128

1 reference

release_lowhqolw5ngnrcu2atxvucl3qi

12 September 2017

0 references

1 reference